Either integrin-α9β1 or TNC antibodies reduce CCL21 mRNA and protein expression to improve hypoimmunity, suggesting that blocking integrin-α9β1 or TNC can alter the SCC tumour microenvironment (76). This evidence concerns the gene CCL21 and neoplasm.